Improving health outcomes through concurrent HIV program scale-up and health system development in Rwanda: 20 years of experienceHost genetics and viral load in primary HIV-1 infection: clear evidence for gene by sex interactionsMolecular and phylogeographic analysis of human immuno-deficiency virus type 1 strains infecting treatment-naive patients from Kigali, RwandaLow primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, RwandaLong-term follow-up of study participants from prophylactic HIV vaccine clinical trials in AfricaSafety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaNew heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data.Promotion of couples' voluntary counselling and testing for HIV through influential networks in two African capital cities.Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa.Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.Knowledge, use, and concerns about contraceptive methods among sero-discordant couples in Rwanda and ZambiaCouples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.Role of traditional birth attendants in preventing perinatal transmission of HIV.Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.Knowledge and perceptions of couples' voluntary counseling and testing in urban Rwanda and Zambia: a cross-sectional household survey.Effect of seasonal variation on adult clinical laboratory parameters in Rwanda, Zambia, and Uganda: implications for HIV biomedical prevention trials.Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.Rwanda 20 years on: investing in lifeDifferences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.Microfluidics-based diagnostics of infectious diseases in the developing world.Failure of a novel, rapid antigen and antibody combination test to detect antigen-positive HIV infection in African adults with early HIV infection.Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa.Human leukocyte antigen B58 supertype and human immunodeficiency virus type 1 infection in native AfricansPerformance of the Focus HerpeSelect-2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countriesTransmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.Indeterminate and discrepant rapid HIV test results in couples' HIV testing and counselling centres in AfricaCreating an African HIV clinical research and prevention trials network: HIV prevalence, incidence and transmission.Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes.What the better half is thinking: A comparison of men's and women's responses and agreement between spouses regarding reported sexual and reproductive behaviors in RwandaRole of donor genital tract HIV-1 diversity in the transmission bottleneck.Twelve-Month Antiretroviral Therapy Suppresses Plasma and Genital Viral Loads but Fails to Alter Genital Levels of Cytokines, in a Cohort of HIV-Infected Rwandan Women.CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data.A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.High Transmitter CD4+ T-Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples.Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection CohortPromotion of couples' voluntary HIV counseling and testing: a comparison of influence networks in Rwanda and Zambia.Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization BreadthA gp41-based heteroduplex mobility assay provides rapid and accurate assessment of intrasubtype epidemiological linkage in HIV type 1 heterosexual transmission PairsEffect of Condom Use on Per-act HSV-2 Transmission Risk in HIV-1, HSV-2-discordant Couples.
P50
Q26824742-0C7641B5-CB3E-4DDE-8FE5-20C44747734DQ28391986-2CACCDDE-A01E-466F-84EE-64E65585E428Q28482242-9A6F5C58-B9BA-473A-B54B-5B4C1AE123B3Q28535266-F3CDF8CA-DA72-4FD2-BD6B-D4DD1D91E454Q28654629-1D3C7182-014E-4B33-B22F-7F22D58BB4E9Q28749224-D86EB78A-B53E-4A79-AFF7-C8241E94FE53Q31160798-C50DF66D-162D-4E45-B413-A485B74357D9Q33309750-EF6D0444-5244-4A79-9E71-43F178395D72Q33402461-8D2D342D-2BC6-4812-A772-2B7896AB2365Q33406262-A2D39DE3-1B0E-44B8-86D0-F90AD2F4A0A3Q33436735-BD7E5C5E-00D1-4E0E-8B22-C518D14C7B3EQ33674757-AE20CD9D-0126-4CCF-8589-F0ABDBB69C68Q33776923-7D785636-C6CB-4E4F-AF54-F1CDBFB8377EQ33808843-CE3DD02F-50BC-43F5-BCA9-BCB3F058DB61Q33881449-04467E29-831F-4083-94DB-7B2DD3A823F2Q33900463-E3ECF966-C765-4A62-A487-900AD291FCD2Q34041851-EBDEDCAE-4153-4285-A01D-299D29F4D2D3Q34102202-1F0234A5-B11E-4AA2-98A2-DF1427AD214AQ34121092-7C89A44A-1B89-4FDA-91F5-F1E1E0104AEBQ34193108-12BF6CA6-6B51-4C05-93CA-4A90FF52A6CFQ34205112-E491B922-F8A3-442C-BA08-5E6F267856E2Q34310188-90DDF7EC-4B1C-408D-8741-8D5B1CCE8493Q34606742-86BBCA29-D272-4A66-9570-F330A9B38F18Q34651577-3DA97DA1-7520-412B-9D7E-2DCBF96AC8F7Q34734012-AF8E1772-D98D-46F4-8CC1-904859B8EC07Q34874985-31B0CF27-0919-4756-B38D-D923EE47AE0BQ34915821-521CD6B3-33AE-4CA2-B1E9-14B1A2E66721Q34989509-3870D9A8-388E-41D4-BC7C-7F9E6F71A447Q35192955-9EB1E771-BF89-4CB5-ABEB-02686321CF67Q35557478-C996405D-E6DC-47F9-8A22-862E725763D0Q35558621-C7C6B8D2-F1F3-4E63-8F3B-04BE099839B2Q35641764-A2B44AEC-BB12-4C84-9901-008502803BE9Q35697246-8DCDE885-8200-4695-8231-D3E2185F442DQ35739841-85741277-2884-4A08-AFCE-FB79C899D43FQ35751134-435F66FF-C0F0-4512-92A3-6F90A5F6B89FQ35894094-C8DCC2B9-4338-45E3-A4F4-F0F35D15EC4DQ36098044-8821701F-953F-4350-AC78-1CB65E3C10F6Q36194234-F3DF2D22-2EBC-4D0F-8852-0A615A3E7868Q36419536-A8DA40A4-5BC0-48D4-B8E6-E05EB096DB4FQ36497840-97A72B7B-5F7D-4187-9F89-F13787807DDA
P50
description
Rwandan scientist and researcher
@en
wetenschapper
@nl
name
Etienne Karita
@en
Etienne Karita
@nl
type
label
Etienne Karita
@en
Etienne Karita
@nl
prefLabel
Etienne Karita
@en
Etienne Karita
@nl
P106
P21
P31
P496
0000-0001-9475-5436